Andreev S.,NRC Institute of Immunology |
Purgina D.,NRC Institute of Immunology |
Bashkatova E.,NRC Institute of Immunology |
Garshev A.,Moscow State University |
And 5 more authors.
Fullerenes Nanotubes and Carbon Nanostructures | Year: 2015
A simple approach for large-scale production of aqueous dispersions of fullerene C60 (nC60) with good stability was developed by mixing a solution of crystalline fullerene in N-methylpyrrolidone (NMP) with water followed by exhaustive dialysis against water. Addition of amino acids or sugars at low concentration before dialysis increases the stability of the dispersion. Measurement of the size and -potential of particles in nC60 showed that their average diameter is 100 nm and charge about -30 mV. IR spectra of the dried dispersions showed the presence of a broadband characteristic for CO bond. Changing the solvent NMP to pyridine does not significantly affect the spectral characteristics of the resulting dispersion. Our data suggest that the fullerene molecule in nC60 is associated with MP and water molecules, and obviously is partially hydroxylated. The proposed method is promising for the preparation of aqueous solutions of endofullerenes. Copyright © Taylor & Francis Group, LLC. Source
Anshakova A.V.,Mendeleev University of Chemical Technology |
Yermolenko Yu.V.,Mendeleev University of Chemical Technology |
Konyukhov V.Yu.,Mendeleev University of Chemical Technology |
Polshakov V.I.,Moscow State University |
And 2 more authors.
Russian Journal of Physical Chemistry A | Year: 2015
The possibility of a intermolecular complex rifabutin (RB)-2-hydroxypropyl-β-cyclodextrin (HP-β-CD) formed as a result of the interaction of the piperidine fragment of the RB molecule and the hydrophobic cavity of the HP-β-CD molecule was found. The stability constant of the intermolecular complex was determined. © 2015 Pleiades Publishing, Ltd. Source
Anshakova A.V.,Mendeleev University of Chemical Technology |
Vinogradov E.V.,National Research Council Canada |
Sedush N.G.,RAS Research Center Kurchatov Institute |
Kurtikyan T.S.,Armenian National Academy of Sciences |
And 6 more authors.
Russian Journal of Physical Chemistry A | Year: 2016
The formulations of rifabutin (RB) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), obtained using different preparation techniques, are studied by means of differential scanning calorimetry and molecular spectroscopy (FTIR, NMR, Raman scattering, and photon correlation light scattering). It is established that molecules of RB do not form inclusion complexes with the molecules of HP-β-CD, and an increase in the solubility of RB determined earlier is caused by the formation of weak intermolecular associates. © 2016, Pleiades Publishing, Ltd. Source
Korkusuz H.,Goethe University Frankfurt |
Ulbrich K.,Goethe University Frankfurt |
Welzel K.,Goethe University Frankfurt |
Koeberle V.,Goethe University Frankfurt |
And 18 more authors.
Molecular Imaging and Biology | Year: 2013
Purpose: In this study, the contrasting properties of human serum albumin nanoparticles (HSA-NPs) loaded with gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) and coated with transferrin in MRI in mice are evaluated. Procedures: HSA-NPs were conjugated with Gd-DTPA (Gd-HSA-NPs) and coupled with transferrin (Gd-HSA-NP-Tf). Mice underwent MRI before or after injection of Gd-DTPA, Gd-HSA-NP, or Gd-HSA-NP-Tf. Results: All the studied contrast agents provided a contrast enhancement (CE) in the blood, heart muscle, and liver. Compared to Gd-DTPA, CE with HSA-NP was achieved at lower Gd doses. Gd-HSA-NP-Tf yielded significantly higher CE than Gd-HSA-NP in the skeletal muscle, blood, cardiac muscle, and liver (p < 0.05). Gd-HSA-NP-Tf achieved a significantly higher CE than Gd-HSA-NP and Gd-DTPA in the blood, cardiac muscle, and liver (p < 0.05). In the brain, only Gd-HSA-NP-Tf was found to cause a significant CE (p < 0.05). Conclusions: The Gd-HSA nanoparticles have potential as MRI contrast agents. In particular, Gd-HSA-NP-Tf has a potential as a specific contrast agent for the brain, while the blood-brain barrier is still intact, as well as in the heart, liver, and skeletal muscle. © 2012 World Molecular Imaging Society. Source
Wohlfart S.,Goethe University Frankfurt |
Khalansky A.S.,Institute of Human Morphology |
Gelperina S.,Nanosystem Ltd. |
Maksimenko O.,Nanosystem Ltd. |
And 3 more authors.
PLoS ONE | Year: 2011
Background: Chemotherapy of glioblastoma is largely ineffective as the blood-brain barrier (BBB) prevents entry of most anticancer agents into the brain. For an efficient treatment of glioblastomas it is necessary to deliver anti-cancer drugs across the intact BBB. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with poloxamer 188 hold great promise as drug carriers for brain delivery after their intravenous injection. In the present study the anti-tumour efficacy of the surfactant-coated doxorubicin-loaded PLGA nanoparticles against rat glioblastoma 101/8 was investigated using histological and immunohistochemical methods. Methodology: The particles were prepared by a high-pressure solvent evaporation technique using 1% polyvinylalcohol (PLGA/PVA) or human serum albumin (PLGA/HSA) as stabilizers. Additionally, lecithin-containing PLGA/HSA particles (Dox-Lecithin-PLGA/HSA) were prepared. For evaluation of the antitumour efficacy the glioblastoma-bearing rats were treated intravenously with the doxorubicin-loaded nanoparticles coated with poloxamer 188 using the following treatment regimen: 3×2.5 mg/kg on day 2, 5 and 8 after tumour implantation; doxorubicin and poloxamer 188 solutions were used as controls. On day 18, the rats were sacrificed and the antitumour effect was determined by measurement of tumour size, necrotic areas, proliferation index, and expression of GFAP and VEGF as well as Isolectin B4, a marker for the vessel density. Conclusion: The results reveal a considerable anti-tumour effect of the doxorubicin-loaded nanoparticles. The overall best results were observed for Dox-Lecithin-PLGA/HSA. These data demonstrate that the poloxamer 188-coated PLGA nanoparticles enable delivery of doxorubicin across the blood-brain barrier in the therapeutically effective concentrations. © 2011 Wohlfart et al. Source